This article first appeared on GuruFocus. AstraZeneca plc (NYSE:AZN) rose 2.16% intraday after J.P. Morgan reiterated an Overweight rating, pointing to six Phase III readouts due in 2027 that together carry more than $10 billion in risk-adjusted peak sales. The bank argues they should improve confidence in the company's ability to keep growing beyond 2030. Warning! GuruFocus has detected 2 Warning Sign with META. Is AZN fairly valued? Test your thesis with our free DCF calculator.AZN GF Value chart J.P. Morgan models peak risk-adjusted sales of $3.2 billion for laroprovstat, an oral PCSK9 inhibitor reading out in the first quarter of 2027, against consensus of $2.4 billion.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.